Pediatric Lymphoma: Clinical Trials

3 trials for Pediatric Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 completed, 1 terminated. 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 13Active not recruiting 1, Completed 1, Terminated 1

Follow Pediatric Lymphoma: new trials by email Literature Review of Pediatric Lymphoma trials Research Report on Pediatric Lymphoma

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
9-ING-41 in Pediatric Patients With Refractory Malignancies.
9-ING-41, Irinotecan, Temozolomide - Refractory Cancer, Refractory Neoplasm
Phase 1TerminatedActuate Therapeutics Inc.402020-06-052025-07-17
Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia
Intravenous fluids - Lymphoma, Acute Lymphoblastic Leukemia
Phase 1CompletedVirginia Commonwealth University102019-10-022024-02-13
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
CLR 131 - Pediatric Solid Tumor, Pediatric Lymphoma
Phase 1Active not recruitingCellectar Biosciences, Inc.302019-04-302026-10-01

Narrower conditions

Diffuse Intrinsic Pontine Glioma (2)  ·  Lymphoma (2)  ·  Neoplasms (2)  ·  Neuroblastoma (2)  ·  Desmoplastic Small Round Cell Tumor (1)  ·  Ependymoma (1)  ·  Glioblastoma (1)  ·  Glioma (1)  ·  Gliosarcoma (1)  ·  Hodgkin Disease (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Medulloblastoma (1)  ·  Meningioma (1)  ·  Neoplasms, Neuroepithelial (1)  ·  Neuroectodermal Tumors, Primitive (1)

Broader conditions

Neoplasms by Histologic Type (3)  ·  Brain Diseases (2)  ·  Brain Neoplasms (2)  ·  Brain Stem Neoplasms (2)  ·  Central Nervous System Diseases (2)  ·  Central Nervous System Neoplasms (2)  ·  Hemic and Lymphatic Diseases (2)  ·  Immune System Diseases (2)  ·  Immunoproliferative Disorders (2)  ·  Infratentorial Neoplasms (2)  ·  Lymphatic Diseases (2)  ·  Lymphoproliferative Disorders (2)  ·  Neoplasms by Site (2)  ·  Neoplasms, Germ Cell and Embryonal (2)  ·  Neoplasms, Glandular and Epithelial (2)

Interventions

3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (1)  ·  CLR1404 (1)  ·  Cyclophosphamide (1)  ·  Irinotecan (1)  ·  Temozolomide (1)  ·  Topotecan (1)

Sponsors

Actuate Therapeutics Inc. (1)  ·  Cellectar Biosciences, Inc. (1)  ·  Virginia Commonwealth University (1)

Countries

United States (3)  ·  Australia (1)  ·  Canada (1)

Top investigators

Cady P Noda, PharmD (1)  ·  Jarrod Longcor (1)

Results publications

PMID 24327518, PMID 27424289, PMID 28053024, PMID 28672195, PMID 29383130, PMID 29846250, PMID 31101621, PMID 31533931, PMID 31831767, PMID 31882719, PMID 39868759